Edwards Lifesciences Corporation ($EW) Stock Forecast: Down 3.4% Today

What is Edwards Lifesciences Corporation?

Edwards Lifesciences Corp. (EW) is a company specializing in medical devices, particularly heart valves and related technologies. The stock had a bearish movement today, experiencing a 3.36% drop.

Why is Edwards Lifesciences Corporation going down?

EW stock is down 3.4% on Mar 31, 2026 14:55

• The bearish movement in Edwards Lifesciences Corp. (EW) stock can be attributed to profit-taking by investors after a period of sustained growth.
• Despite positive developments such as the FDA clearance for the AI heart valve repair solution developed in collaboration with Philips, the market may have reacted negatively due to high expectations already priced into the stock.
• The positive 2-year survival data from the TRISCEND II trial for the EVOQUE transcatheter tricuspid valve replacement system could have been overshadowed by broader market sentiment or sector rotation.
• Investors might be cautious about the stock's valuation, considering the recent price pressure and fluctuations, leading to the bearish movement despite the company's strong management efficiency and positive long-term performance.

EW Price Chart

EW Technical Analysis

EW News

Edwards Lifesciences Hits Day Low of $78.58 Amid Price Pressure

Edwards Lifesciences Corp. (EW) experienced a stock decline, hitting an intraday low of $78.58, with a 3.36% drop. The stock has seen decreases over the past week and month but maintains a positive return over the past year. Despite fluctuations, the company shows strong management efficiency and a fair valuation with a price-to-book ratio of 4.62.

https://www.marketsmojo.com/news/stocks-in-action/edwards-lifesciences-hits-day-low-of-7858-amid-price-pressure-3926353

Philips Wins FDA 510(k) Clearance for AI Heart Valve Repair Solution

Philips has received FDA 510(k) clearance for its AI-enabled solution, EchoNavigator R5.0 with DeviceGuide, developed in collaboration with Edwards Lifesciences. This innovation assists physicians during minimally invasive mitral valve repair procedures by providing real-time AI-based visualization and navigation. The solution is expected to bolster Philips' market position, drive equipment sales, and ensure strong customer retention due to its deep integration with existing Philips platforms.

https://finance.yahoo.com/sectors/healthcare/articles/philips-wins-fda-510-k-175800206.html

Heart valve trial shows 2-year survival edge for Edwards device

Edwards Lifesciences presented new 2-year data from its TRISCEND II trial at ACC.26, showing significant and sustained patient benefits for its EVOQUE transcatheter tricuspid valve replacement (TTVR) system. The results indicated lower all-cause mortality, near-elimination of tricuspid regurgitation, improved health status, and no added device-related risk, even after accounting for patient crossover from the medical therapy control group. This data builds upon previous findings and underscores the benefits and need for TTVR therapy for patients with severe tricuspid regurgitation.

https://www.stocktitan.net/news/EW/two-year-data-on-edwards-lifesciences-evoque-system-continue-to-8xmwuw6r9gvm.html

4,700 cancer providers can now order Abbott tests in their records system

Abbott and Flatiron Health have integrated Abbott's Precision Oncology portfolio into Flatiron's OncoEMR platform, allowing 4,700 providers at over 1,600 community cancer centers to order Abbott tests and receive results directly within their clinical workflow. This integration is designed to streamline the process, reduce administrative burden, and accelerate informed treatment decisions for cancer patients. The available tests include Oncotype DX Breast Recurrence Score®, OncoExTra®, Oncodetect®, and Riskguard®, aiming to provide a unified experience for clinicians.

https://www.stocktitan.net/news/ABT/abbott-expands-access-to-precision-oncology-portfolio-through-s94qbijartvf.html

A single Gemini dose restored immune response for 7 days in CKD study

Revelation Biosciences (NASDAQ: REVB) announced additional positive data from its PRIME study, showing that a single dose of its experimental drug Gemini durably normalized cellular inflammation and restored immune responsiveness for up to 7 days in patients with stage 3-4 chronic kidney disease (CKD). Over 85% of CKD patients exhibited elevated cytokines prior to dosing, with Gemini significantly reducing these and restoring normal responsiveness to LPS stimulation. This data supports the planned initiation of a pivotal AKI clinical study later in the year, despite a historical pattern of negative stock reactions to positive clinical trial news.

https://www.stocktitan.net/news/REVB/revelation-biosciences-inc-presents-additional-positive-data-from-g4xbk70pxj21.html

Trending Today

Algorand ($ALGO) Crypto Forecast: Up 5.2% Today

Crude Oil ($CRUDE) Commodity Forecast: Up 5.0% Today

Natural Gas ($GAS) Commodity Forecast: Down 5.0% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.2% Today

Pool Corporation ($POOL) Stock Forecast: Down 6.6% Today

Torchmark Corporation ($GL) Stock Forecast: Up 5.1% Today

Vaulta (prev.EOS) ($A) Crypto Forecast: Down 5.2% Today

Duolingo Inc. ($DUOL) Stock Forecast: Down 5.1% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.2% Today

Thermo Fisher Scientific Inc ($TMO) Stock Forecast: Down 10.0% Today

Edwards Lifesciences Corporation Price History

31.02.2026 - EW Stock was down 3.4%

• The bearish movement in Edwards Lifesciences Corp. (EW) stock can be attributed to profit-taking by investors after a period of sustained growth.
• Despite positive developments such as the FDA clearance for the AI heart valve repair solution developed in collaboration with Philips, the market may have reacted negatively due to high expectations already priced into the stock.
• The positive 2-year survival data from the TRISCEND II trial for the EVOQUE transcatheter tricuspid valve replacement system could have been overshadowed by broader market sentiment or sector rotation.
• Investors might be cautious about the stock's valuation, considering the recent price pressure and fluctuations, leading to the bearish movement despite the company's strong management efficiency and positive long-term performance.

31.09.2025 - EW Stock was up 0.6%

• The bullish movement in Edwards Lifesciences (EW) stock today can be attributed to:
• Positive analyst upgrades indicating a favorable outlook on the company's performance.
• Anticipation and optimism surrounding the upcoming Q3 earnings report, with analysts projecting strong results.
• The news of an investigation by a law firm may have had a minimal impact on the market movement, as investors focused more on the positive analyst upgrades and earnings projections.

28.09.2025 - EW Stock was up 7.2%

• The optimistic movement in EW stock can be linked to favorable analyst estimates for its Q3 earnings, indicating strong performance and potential growth outlook.
• Despite ongoing investigations into potential breaches of fiduciary duties by EW's directors and officers, investors maintain a positive outlook on the company's future, influencing the bullish market trend.
• Investor confidence appears to be driven by the company's solid fundamentals and growth prospects rather than the legal scrutiny, resulting in the upward movement of the stock price.

24.03.2025 - EW Stock was up 7.2%

• Strong bullish movement in the stock today.
• Analysts upgraded the stock as the growth outlook brightened, with Q1 sales rising 58% YoY and beating consensus estimates.
• Q1 earnings and revenues surpassed expectations, leading to a raised sales view for 2025.
• The market responded positively to the company's performance and optimistic outlook, driving the stock price higher.

25.06.2025 - EW Stock was up 3.9%

• Edwards Lifesciences (EW) saw a significant uptrend in the market today.
• This rise is linked to the company outperforming expectations in their second-quarter financial results, exceeding projected earnings.
• Additionally, analysts raised their forecasts for EW following the strong Q2 results, further boosting investor confidence.
• The positive market response to the company's strong performance and positive outlook led to an increase in the stock price.

25.06.2025 - EW Stock was up 6.6%

• Q2 results for Edwards Lifesciences (EW) are believed to have surpassed expectations from analysts.
• The company's strong performance in key metrics may have boosted investor confidence, influencing the bullish movement.
• The robust Q2 performance could signal innovation and market responsiveness, attracting more investors and potentially increasing the stock price.

25.06.2025 - EW Stock was up 5.2%

• Edwards Lifesciences (EW) experienced a strong bullish movement today following its Q2 earnings report.
• The company reported Q2 sales of $1.53 billion, surpassing the estimated $1.49 billion, and an EPS of $0.67, higher than the expected $0.62.
• The positive results were primarily driven by strong performance in its transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) segments.
• Analysts have increased their forecasts for EW after the robust Q2 results, with a price target also being raised to $101 on the company's growth momentum. The raised FY25 sales outlook further contributed to the bullish sentiment surrounding the stock.

11.01.2026 - EW Stock was up 1.1%

• An affirmation of a "Buy" rating for Edwards Lifesciences (EW) with a target price of $103.00 USD has enhanced investor confidence and sparked a bullish movement in the stock.
• Despite falling short of the EPS estimate by $0.04, Edwards Lifesciences delivered robust Q4 2025 sales growth, primarily from TAVR sales, and expressed optimism about its 2026 adjusted EPS and full-year sales growth forecast. This positive outlook has likely contributed to the bullish momentum.
• Strong Q4 2025 results, featuring double-digit revenue growth and positive projections for growth avenues like the LAA market, have reinforced investor confidence in Edwards Lifesciences, adding fuel to the bullish trend.
• Overall, positive analyst ratings, robust sales growth, and a promising future outlook have driven Edwards Lifesciences' stock on an upward trajectory today.

27.09.2025 - EW Stock was up 5.8%

• The bullish movement in EW stock could be attributed to an investigation into potential breaches of fiduciary duties by the company's directors and officers.
• Investors may interpret this investigation as a sign of accountability and transparency within the company, leading to increased confidence in EW's corporate governance practices.
• This news might have reassured shareholders and attracted new investors, contributing to the positive market movement of EW stock today.

27.02.2026 - EW Stock was down 5.3%

• Edwards Lifesciences (EW) witnessed a downward trend despite recent positive developments related to Vanguard subsidiaries' holdings in the company.
• Market sentiment towards medical device firms, exacerbated by enVVeno Medical Corp's strategic shift and regulatory hurdles, likely affected Edwards Lifesciences' stock performance.
• Heightened investor attention on Abbott Laboratories' stock following a slowdown in diagnostics may have contributed to the bearish movement in the medical technology sector, impacting companies like Edwards Lifesciences.
• Although outperforming competitors on a recent trading day, prevailing market conditions and sector-specific obstacles appear to have overshadowed the positive momentum for Edwards Lifesciences, resulting in the downward movement.

27.02.2026 - EW Stock was down 5.1%

• The bullish movement in AstraZeneca's shares could have attracted investors away from Edwards Lifesciences, impacting its stock negatively.
• The positive projections for the global cardiac ablation devices market might have shifted investor focus towards competitors in the healthcare sector, leading to a bearish trend for Edwards Lifesciences.
• Information about Vanguard reporting zero holdings in Edwards Lifesciences could have caused uncertainty among investors, contributing to the bearish movement in the stock.
• The strategic shift and challenges faced by enVVeno Medical Corp could have highlighted the competitive landscape in the healthcare industry, potentially affecting investor sentiment towards companies like Edwards Lifesciences.

01.09.2025 - EW Stock was down 3.7%

• The bearish movement in Edwards Lifesciences stock today could be attributed to:
• Profit-taking by investors after a prolonged period of outperformance in the market.
• Concerns about potential competition or regulatory challenges in the medical technology sector.
• Overall market sentiment affecting healthcare stocks, leading to a broader sell-off in the industry.
• Technical factors triggering a short-term downward trend in the stock price.